The award honors a life sciences company in the Greater Philadelphia region that in the opinion of the judges "makes medical miracles in our community." CSL Behring was selected based on its portfolio of life-enhancing and life-saving therapies for people with rare and serious diseases that include hemophilia, von Willebrand disease, factor deficiencies, immune deficiencies, hereditary angioedema and inherited respiratory disease.
CSL Behring is one of more than 400 life sciences companies in the eight-county Greater Philadelphia region – Philadelphia, Bucks, Delaware, Montgomery and Chester in Pennsylvania, and Burlington, Camden and Gloucester in New Jersey.
"CSL Behring is honored to receive the Life Sciences Company of the Year Award," says CSL Behring President Paul Perreault. "The award is an affirmation of our commitment to providing safe and effective therapies to improve the lives of patients with rare and serious medical conditions.
"At a time when many pharmaceutical and biopharmaceutical companies have been cutting their R&D budgets, CSL Behring has continued to increase its investment in this vital area. This is reflected in CSL’s promising pipeline that includes several novel recombinant factor therapies for treating congenital bleeding disorders, products for treating acquired bleeding disorders, and reconstituted HDL for treating patients with heart disease."
The Life Sciences Company of the Year award is the most recent in a series of recognitions for CSL Behring's innovation in providing important therapies. Earlier this year the National Organization for Rare Disorders (NORD) honored CSL Behring for "new treatments brought to market for patients with rare diseases." NORD also honored CSL Behring in 2009 for developing and marketing an innovative treatment for acute bleeding disorders.
About CSL Behring
CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide.
CSL Behring therapies are indicated for the treatment of coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease. The company’s products are also used in cardiac surgery, organ transplantation, immune thrombocytopenic purpura, burn treatment and to prevent hemolytic disease of the newborn.
CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited (ASX:CSL), a biopharmaceutical company headquartered in Melbourne, Australia. For more information, visit www.cslbehring.com.
Manager Corporate Communications